Industry
Ongoing Phase 3 trial built on positive data from Phase 2 HERACLES study and ongoing early access program (EAP) in France: both datasets showed that MaaT013 was well-tolerated in immunocompromised…
Industry
Sponsored by
The microbiological laboratory applying AI to specific analysis activities.
Topical treatment is achieving all endpoints for efficacy and safety in mild, moderate, and severe atopic dermatitis.
The collaboration will focus on various aspects of the human microbiome that could benefit new product development.
The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis.
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x.
MAP 315, is a novel live biotherapeutic product being developed for the treatment of ulcerative colitis and was discovered and developed using Microba’s data-driven Therapeutics Platform.
Biofarma Group's R&D to support people in the pre-depressive phase.
Ensemble No.3 (ENS-003) is in development to address vulvovaginal candidiasis – a vaginal yeast infection for which antifungal treatments offer limited protection from recurrence.
A large Korean population study provides scientific evidence that altering the gut microbiome composition through dietary habit change can help prevent and manage the hypertension.
